天天背单词应用上线拉 快速记忆，轻松突破英语障碍 火热报名 — 在线音乐 — 来宾名单
在线医学课堂荣誉上线 国内首家一站式医学课堂 病理生理学 — 病理学 — 儿科学 — 遗传学
看看今天战友们都干了什么？ — 分享精彩 — PHP培训 CT读片 — MRI病例 — Discuz!NT3.1发布 20000张皮肤科图片大放送 — 国内最专业的医学图片库
| 11月25 星期三（每日健康新闻）----最新研究显示，新辅助化疗中加用西妥昔单抗可以缩小瘤体并能使无法切除的肝转移的结直肠癌变为能完整切除。 研究人员在11月24日在柳叶刀肿瘤版在线发表文章说明，超过一半以上的结直肠癌会发生其他部位的远处转移。最常见的会转移到肝脏。完整切除肝转移瘤会治愈这些病人，然而大约80%的病人在就诊时病灶无法切除并且预后很差。 先前的研究显示以伊利替康或奥沙利铂为基础的化疗可以增加手术切除机会。最新的研究看出如果加用西妥昔单抗（又名爱比妥）可以明显增加这种手术切除的优势。 此研究的作者，德国德累斯顿Carl Gustav Carus大学医院的Gunnar Folprecht教授，及德国和奥地利的同事发现，加用西妥昔单抗的治疗方案明显增加了手术切除的比率。而总体上并没有发生明显的毒副反应。 Folprecht和同事们写到，我们的数据表明西妥昔单抗联合化疗的结果明确证实了明显增加肿瘤缓解率，鉴于在转移性结直肠癌的最新研究，进一步强化治疗的价值尚需进研究。 WEDNESDAY, Nov. 25 (HealthDay News) -- Adding the drug cetuximab to neoadjuvant chemotherapy can shrink tumors and boost the odds of successful surgery in colorectal cancer patients with inoperable metastatic liver lesions, new research suggests. Tumors spread to other parts of the body in more than half of patients with colorectal cancer. Most commonly, the cancer spreads to the liver. Removing the tumors in the liver can cure patients, but about 80 percent have inoperable disease and a poor prognosis when they see doctors, the researchers explain in the Nov. 24 online edition of The Lancet Oncology. Previous research suggests that neoadjuvant treatment with irinotecan- or oxaliplatin-based chemotherapy can make surgery more likely to succeed. The new study aimed to see if addition of the drug cetuximab, also known as Erbitux, would help patients even more. The study authors, Gunnar Folprecht, from University Hospital Carl Gustav Carus in Dresden, Germany, and colleagues from Germany and Austria found that treatment with cetuximab boosted the proportion of tumors that could be treated with surgery. The treatment, in general, didn't have serious side effects. "Our data suggest that treatment with cetuximab and chemotherapy results in high confirmed tumor response rates ... leading to ... increased respectability," Folprecht and colleagues wrote. "In the light of recent studies in metastatic colorectal cancer, the value of further treatment intensification will be investigated." |
医学岛 ( 京ICP备09108294号 )
GMT+8, 2010-9-6 10:35
Powered by Discuz! X1.5RC
© 2001-2010 Comsenz Inc.
